Patients with low-grade bladder tumors benefit from less-frequent, less-invasive follow-up
This article has no abstract so we have provided the first paragraph of the full text.
More than half of all patients diagnosed with bladder cancer have low-grade, noninvasive papillary tumors. Current treatment comprises initial transurethral resection (TUR), sometimes with immediate chemotherapy. Patients are then followed up intensively, since this type of bladder tumor recurs frequently; however, low-grade bladder tumors rarely progress in grade or become life threatening, so repeat surveillance every 3 months by cystoscopic examination and TUR under anesthesia might burden patients with years of frequent, uncomfortable, invasive and potentially unnecessary procedures.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.